Profile: Stemline Therapeutics Inc (STML.OQ)
27 Mar 2015
Stemline Therapeutics, Inc. incorporated on August 8, 2003, is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701. The indication for SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and advanced acute myeloid leukemia (AML). SL-701 is a subcutaneously-administered therapeutic cancer vaccine comprised of multiple synthetic peptides. Stemline’s StemScreen consists of StemScreen-1 and StemScreen-2 for the identification of CSC-directed compounds.
SL-401 is a clinically active targeted therapy directed to the interleukin-3 receptor, or IL-3R. IL-3R is overexpressed on CSCs and/or more mature cancer cells derived from CSCs (i.e., tumor bulk) of multiple hematologic cancers including acute myeloid leukemia, or AML, chronic myeloid leukemia, or CML, myelodysplastic syndrome, or MDS, certain lymphomas including Hodgkin’s disease, multiple myeloma, or MM, and multiple rare hematologic malignancies such as blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and others. It is in the Phase I/II trials.
SL-701 is an immunotherapy designed to activate the immune system to attack tumors. A multicenter clinical trial with SL-701 is currently open and actively accruing adult patients with glioblastoma multiforme (GBM) in first recurrence. Previously, an earlier version of the therapy demonstrated clinical activity, including durable CRs and partial responses (PRs), in Phase I/II trials in adults and children with advanced brain cancers.
StemScreen-1 is a discovery platform to identify compounds that target and kill CSCs. It involves CSC isolation and target identification; in silico screen which identifies compound classes that interact with CSC targets, and battery of anti-CSC functional assays that test compounds for activity against CSCs both in vitro and in vivo.
StemScreen-2 is a high throughput screen currently in development. StemScreen-2 takes advantage of a landmark discovery that cancer cell lines harbor CSCs. This technology enables the development of high throughput screens for compounds that target CSCs.
The Company competes with Astellas Pharma US, Inc., Boehringer Ingelheim GmbH, Geron Corp., GlaxoSmithKline plc, Macrogenics Inc., Micromet, Inc. (an Amgen, Inc. Company), Pfizer Inc., Roche Holding AG and Sanofi U.S. LLC.
Stemline Therapeutics Inc
750 Lexington Avenue, Eleventh F
NEW YORK NY 10022